II. Epidemiology
- Age of onset
- Type I Diabetes Mellitus: 22 (mean age of onset)
- Type II Diabetes Mellitus: 30 to 50 years
- Most common in women by 3 fold
III. Pathophysiology
- Unknown etiology
- Appears related to microvascular changes
IV. Associated Conditions: Diabetes Mellitus
- Necrobiosis patients with comorbid diabetes: 11-65%
- Prevalence of necrobiosis in Diabetes: 0.3 to 1.6%
- Necrobiosis predicts of future diabetes development
V. Symptoms
- Lesions are painless in most cases
VI. Signs
- Slowly growing oval atrophic Plaques
- May be several centimeters in size
- Initial
- Erythematous Plaque with raised irregular border
- Later
- Yellow brown waxy central atrophic area
- Distribution
- Telangiectases (subcutaneous vessels)
- Lesions may ulcerate with Trauma (risk of infection)
- Associated Neuropathy in 50% of patients
- Decreased pinprick and fine Touch Sensation
VII. Labs: Biopsy (often not needed)
- Necrobiosis of Collagen
- Histiocytes and Lymphocytes surround Collagen
- Inflammation around blood vessels
VIII. Differential Diagnosis
- Dermatopathology
- Clinical
- Rheumatoid Nodules in Rheumatoid Arthritis
- Erythema Nodosum
IX. Management
-
Corticosteroids
- Clobetasol Propionate under Occlusion for 6 weeks
- Intralesional Kenalog 10 mg/ml (dilute to 2.5 mg/ml)
- Oral Prednisone for 5 weeks
- Topical Psoralen with Ultraviolet A Exposure (PUVA)
- Inhibition of Platelet aggregation
- Pentoxifylline (Trental) 400 mg PO tid for 4-8 weeks
- Aspirin 325 mg PO qd for 3 to 7 months
- Dipyridamole (Persantine) 150-200 mg PO divided qid
- Skin Grafting or local excision
- Not recommended due to high recurrence rate
- Extensive skin involvement refractory to above
- Other treatment modalities
- Laser treatment for Telangiectasias
- Benzoyl Peroxide for ulcerated lesions
X. Course
- Gradually resolves over 6-12 year period
- Residual atrophy persists after resolution
XI. References
- Habif (1996) Clinical Dermatology, Mosby, p. 784-5
- Ferringer (2002) Dermatol Clin 20(3):483 [PubMed]
- Lowitt (1991) J Am Acad Dermatol 25:735-48 [PubMed]
- Paron (2000) Prim Care 27(2):371-83 [PubMed]